{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:29:05Z","timestamp":1791163745470,"version":"4.1.0"},"reference-count":19,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T00:00:00Z","timestamp":1291075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T00:00:00Z","timestamp":1291075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Neurol"],"published-print":{"date-parts":[[2011]]},"abstract":"<jats:p>&lt;i&gt;Background\/Aims:&lt;\/i&gt; In treating myasthenia gravis (MG), our aims were to achieve early minimal manifestations (MM) by performing early aggressive therapy (EAT) using plasmapheresis and high-dose intravenous methylprednisolone, and then to maintain the status with low-dose oral corticosteroids (EAT strategy). We examined the merits of the EAT strategy. &lt;i&gt;Methods:&lt;\/i&gt; We retrospectively analyzed long-term effects of the EAT strategy (duration of therapy: 4.1 years) for 49 de novo MG patients and compared the effects to those of high-dose oral prednisolone therapy for 22 patients. &lt;i&gt;Results:&lt;\/i&gt; The EAT group achieved marked early improve- ment with much lower doses of oral prednisolone compared to the high-dose prednisolone group. The patients who achieved MM with prednisolone \u22645 mg\/day were more frequent in the EAT group at both 1 year (57.1 vs. 4.5%) and final observation (77.6 vs. 27.3%). Both new-onset diabetes and patients who had complained of moon face were less frequent in the EAT group. However, in the EAT group, due to a temporary inability to maintain MM, additional short-term hospitalizations to return to MM by EAT were required. &lt;i&gt;Conclusions:&lt;\/i&gt; The EAT strategy has advantages of early improvement with less frequent steroid-related complications. The labor and cost required are evident disadvantages.<\/jats:p>","DOI":"10.1159\/000322497","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T04:43:12Z","timestamp":1291092192000},"page":"16-22","source":"Crossref","is-referenced-by-count":50,"title":["Early Aggressive Treatment Strategy against Myasthenia Gravis"],"prefix":"10.1159","volume":"65","author":[{"given":"Yuriko","family":"Nagane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiaki","family":"Utsugisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2010,11,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1126%2Fscience.180.4088.871"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2FS1474-4422%2809%2970063-8"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1586%2F14737175.9.3.351"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002%2Fmus.20030"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002%2Fana.410150316"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212%2F01.wnl.0000312373.67493.7f"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3109%2F08916930903518107"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002%2Fmus.20950"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3109%2F10673229809000307"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1196%2Fannals.1405.040"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136%2Fjnnp.74.8.1105"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212%2F01.wnl.0000176067.32186.a3"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159%2F000062987"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159%2F000085833"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2879%2990823-7"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136%2Fjnnp.57.5.578"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM198703193161205"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1749-6632.1998.tb11017.x"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1212%2F01.wnl.0000256698.69121.45"}],"container-title":["European Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/322497","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/322497","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/322497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:11:43Z","timestamp":1745421103000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000322497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,30]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,1,1]]},"published-print":{"date-parts":[[2011,1,25]]}},"URL":"https:\/\/doi.org\/10.1159\/000322497","archive":["Portico"],"relation":{},"ISSN":["0014-3022","1421-9913"],"issn-type":[{"value":"0014-3022","type":"print"},{"value":"1421-9913","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,30]]}}}